META:PHI in Primary Care: Implementing Best Practices for Addictions

Slides:



Advertisements
Similar presentations
Abuse or Dependence? Assessing the Alcoholic patient in the Clinic. Antoni Gual Alcohol Unit Psychiatry Department Neurosciences Institute.
Advertisements

Substance Related Disorders
Judith Martin, MD Medical Director of Substance Use Services, SFDPH
13 Principles of Effective Addictions Treatment
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
DSM – 5 Substance-Related and Addictive Disorders
What’s New in DSM-5 For Clinicians Working with Mandated Populations State Specialty Court Conference DuAne L. Young The Change Companies®
University Hospital “Sisters of Charity” Psychiatric Clinic Vinogradska c. 29, 1000 Zagreb, Croatia Davor Moravek Addiction and psychotic.
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
Sublingual Buprenorphine and Pain
Why Not Use the DSM-IVR for Diagnosing Addiction? Reason #147: Inadequacies of using qualitative indices for a quantitative problem.
Practice Principles and Pharmacology CSD 5970 Counseling the Chemically Dependent.
SBIRT Module 2: Screening for Substance Use Problems in Primary Care UCSF SBIRT Collaborative Education Project Janice Tsoh, PhD.
Withdrawal From Treatment. 3 Situations 1. Voluntary – patient and doctor agree it is time to taper and try to stop treatment 2. Voluntary – patient insists.
Medical Model of Addiction
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Chapter 4 Screening and Assessment of Alcohol/Drug Problems.
©2010 McGraw-Hill Higher Education. All rights reserved. Chapter 4 Definitions of Substance Abuse, Dependence, and Addiction.
North Carolina TASC Clinical Series Training Module Eight: DSM -IV.
DOUGHNUTSDOUGHNUTS. Opioid Agonist Therapy The Skinny on Methadone et al.
Assessment of Substance Use Disorders
Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 17 Substance-Related Disorders – Focus on Alcoholism.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Problem alcohol use among drug users: Clinical guidelines development for primary care Jan Klimas, Catherine Anne Field, Walter Cullen & Guideline Development.
OPIOID SUBSTITUTION THERAPY
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Defining substance abuse Health Psychology. Introduction to Substances.
Buprenorphine Treatment for Opioid Dependence CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for.
Problem Behaviors Norman Wetterau. Less serious Ran of out pills three days early After one year lost pills Had a headache and a friend gave her a vicodin.
Ph: Disclaimer: Information on this page is not a substitute for medical consultation.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
Substance abuse. Definition It’s a mental disorder that shows symptoms and maladaptive behavioral changes with the use of substances that affect the CNS.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
Shine the Light on Substance Use Disorders Presented by Student Alliance for Mental Health.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Management of Opioid Use Disorders Education Rounds for ED and Hospital Counsellors, Crisis Workers and Withdrawal Management Staff.
December 10, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
Current Concepts in Pain Management
What does pharmacology have to do with treatment of heroin addiction?
Medi-cal covered inpt tx in SoCo?
Acute Pain Management for Patients Receiving Buprenorphine Therapy
Methadone and Suboxone
Case Presentations.
COMMONLY USED TERMS DR. JOSEPH B. FAMA FPSMS CLINICAL DEPARTMENT HEAD DOH-DRUG TREATMENT AND REHABILITATION CENTER.
Drug Use as a Social Problem
DSM-IV-TR, APA, 2000 Criteria for Substance Dependence:
A State Targeted Response to the Opioid Crisis:
Substance Use Disorders
Treating Opioid Withdrawal with Buprenorphine/Naloxone
Assessing Opioid Use Disorder, part 1
Distributing Naloxone in the Emergency Department
META:PHI in Primary Care: Implementing Best Practices for Addictions
META:PHI in Primary Care: Implementing Best Practices for Addictions
META:PHI in Primary Care: Implementing Best Practices for Addictions
META:PHI in Primary Care: Implementing Best Practices for Addictions
Off-label use means all uses of a marketed drug not detailed in the summary of the product characteristics including therapeutic indication, use in age-
Office of Aerospace. Medicine
Dr. Meldon Kahan Provincial Counsellor Call April 12, 2019
Town of Collingwood Council September 10th, 2018 Mia Brown RN BScN
ADDICTION
Risk Management During Opioid Analgesic Prescribing for Chronic Pain
Treating Opioid Withdrawal with Buprenorphine/Naloxone
Medication Assisted Treatment of Opioid Use Disorder
Treating Opioid Use Disorder
Treatment of Opioid Use Disorder
Harm Reduction Approach to Treatment of All Substance Use Disorders
Bassett-UMass MAT ECHO.
Opiate misuse among our seniors
Bassett-UMass MAT ECHO.
Acute Pain Management & Addiction
Presentation transcript:

META:PHI in Primary Care: Implementing Best Practices for Addictions Managing Opioid Use Disorders in Chronic Pain Patients

What is META:PHI? Mentoring, Education, and Clinical Tools for Addiction: Primary Care–Hospital Integration Collaborative project to implement integrated care pathways for addiction throughout Ontario Partnership between hospitals, withdrawal management services, FHTs, CHCs, and community agencies Goals: Improve care for patients with addictions Improve care provider experience Improve population health Reduce service use Provide sustainable care

How it works Patients presenting with addiction-related concerns receive evidence-based interventions and are referred to rapid access addiction medicine (RAAM) clinics for treatment RAAM clinics offer substance use disorder treatment on walk-in basis; no formal referral/appointment needed Patients stabilized at RAAM clinic referred back to primary care for long-term addiction treatment (with ongoing support from RAAM clinic as required) Key components: Integration of care at hospital, RAAM clinic, primary care Training, support, and mentorship from addictions specialists Capacity-building

Role of PCPs With support from META:PHI team: Follow best practices for prescribing opioids Screen and diagnose patients for substance use disorders Refer patients to treatment at RAAM clinic when necessary Take over long-term addiction care for patients (with ongoing support from RAAM clinic doctor)

Identifying and diagnosing Opioid use disorder (OUD)

OUD in pain patients OUD can occur as a complication of opioid therapy All patients on opioid therapy for chronic pain should be regularly monitored for signs of OUD Risk factors < 40 years old Male Concurrent substance use disorder (alcohol, benzodiazepines, etc.) Active mental illness (depression, anxiety, PTSD, etc.)

OUD DSM-V criteria (1) Impaired control: Opioids taken in larger amounts or for a longer period than intended There is a persistent desire or unsuccessful efforts to cut down or control opioid use A great deal of time is spent obtaining or using opioids, or recovering from their effects There are cravings or a strong desire to use opioids

OUD DSM-V criteria (2) Social impairment: There is recurrent opioid use resulting in a failure to fulfill important role obligations at work, school, or home There is continued use despite persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of opioids Important social, occupational, or recreational activities are given up or reduced because of opioid use

OUD DSM-V criteria (3) Risky use: There is recurrent opioid use in situations where it is physically hazardous Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is caused or exacerbated by opioids

OUD DSM-V criteria (4) Physiological dependence: Tolerance: There is either a need for markedly increased amounts of opioids to achieve intoxication or desired effect or there is a markedly diminished effect with continued use of the same amount of opioids Withdrawal: There is either characteristic withdrawal syndrome for opioids or opioids are taken to relieve or avoid withdrawal symptoms

Clinical features of OUD in pain patients High opioid dose for underlying condition Aberrant behaviours: Running out early, crushing/biting oral tabs, accessing opioids from other sources Strong resistance to switching or tapering Importance attached to drug outweighs analgesic benefit (e.g., “Pain is 10/10, medication only takes edge off, but I would die if you stopped it”) Binge rather than scheduled use Deteriorating mood and functioning Concerns expressed by friends/family Reports recurrent, frightening withdrawal symptoms May acknowledge immediate mood improvement after dose

Presenting a diagnosis Be clear and non-judgmental Inform patient that their opioid use is harming them and that treatment will improve their pain, mood, and functioning Do not abruptly stop opioid prescribing This puts patient at increased risk of overdose death Give patient harm reduction advice Offer treatment

OUD treatment options

Treatment options Abstinence-based treatment Structured opioid therapy Opioid maintenance therapy

Abstinence-based psychosocial treatment Treatment goal: Cessation of all opioids (sometimes including opioid agonist treatment) Advantages Often preferred by patients to long-term opioid agonist treatment Often provides participants with a sense of community Gives structure to participants’ lives Disadvantages Does not provide physical relief from withdrawal symptoms/cravings, which can last for weeks or months Increased risk of relapse and opioid overdose; patients should be given harm reduction advice

Harm reduction advice (1) Never use opioids alone Make sure you and your friends know the signs of overdose (pinpoint pupils, falling asleep, slowed/stopped breathing, bluish skin around lips or under nails) Always carry naloxone If a friend has overdosed: Shake them and call their name Call 911 Administer naloxone and start chest compressions If you are taking opioids after a period of abstinence (even a few days), take a much smaller dose than you used to

Harm reduction advice (2) Only medications obtained from a prescription and purchased at a pharmacy are guaranteed to be what they are supposed to be Many opioids (and other drugs, such as cocaine) are laced with fentanyl Fentanyl is very potent and can be lethal even in tiny amounts Do not inject opioids Do not mix opioids with other substances, especially alcohol or benzodiazepines

Structured opioid therapy (1) Opioid prescribing under conditions that limit misuse Indications Has or is at high risk for OUD Has pain condition requiring opioid therapy Only uses opioids supplied by one prescriber Does not alter route of delivery (inject/crush oral tabs) Is not currently addicted to alcohol or other drugs

Structured opioid therapy (2) Protocol Taper dose: Typically 10% of total daily dose at each visit, no more than 10% of total daily dose every 1–2 weeks Taper more slowly when 1/3 of total dose is reached Dispense small amounts frequently Do not refill if patient runs out early Monitor with office visits, pill counts, urine drug screens Switch to opioid maintenance therapy if structured opioid therapy fails (i.e., patient continues to use more than prescribed)

Opioid agonist therapy (1) Substitution of illegal and/or euphoria-inducing opioid with longer-acting, less euphoric opioid Relieves withdrawal symptoms/cravings for 24 hours Indications Has OUD Failed at/not a candidate for opioid tapering Acquires opioids from multiple sources (e.g., other doctors, friends/relatives, the street) Alters route of delivery (inject/crush oral tabs) Current risky use of alcohol or other drugs

Opioid maintenance therapy (2) Maintenance therapy has historically used methadone Full, potent opioid agonist Risk of sedation/overdose Requires a federal exemption to prescribe Another option is buprenorphine Partial opioid agonist with a ceiling effect Even very high doses rarely cause respiratory depression (unless combined with alcohol/sedatives) Binds tightly to receptors, displacing other opioids Usually combined 4:1 with naloxone as abuse deterrent Can be prescribed by any doctor in Ontario

Prescribing buprenorphine

Why prescribe buprenorphine? (1) Attending a methadone clinic is not always possible: Patient reluctance No local clinic Long waiting list Larger methadone clinics sometimes have rigid rules (e.g., frequent urine drug screens) and often do not provide counselling or primary care Evidence has demonstrated that buprenorphine in primary care settings is as effective as in specialized settings Patients often prefer receiving buprenorphine from their PCP: Less stigmatizing Patient has close relationship with PCP

Why prescribe buprenorphine? (2) Prescribing buprenorphine to a patient with OUD is much more satisfying than prescribing opioids: Patients usually feel and function better Behaviours associated with OUD (running out early, missed appointments, drug seeking, etc.) usually resolve Patients usually very grateful for PCP’s role in their recovery

Initiation Biggest risk of initiation is precipitated withdrawal Buprenorphine displaces currently attached opioids Causes rapid onset of intense withdrawal Not medically dangerous but can deter patients from treatment Before first dose, patient should have no opioid in serum and be in moderate withdrawal Measure withdrawal using Clinical Opioid Withdrawal Scale (COWS)

COWS Resting heart rate 1 2 4 Sweating 3 Restlessness 5 Pupil size (≤ 80) 1 (81–100) 2 (101–120) 4 (121+) Sweating 3 Restlessness 5 Pupil size Bone/joint aches Runny nose/tearing GI upset Tremor Yawning Anxiety/irritability Gooseflesh skin TOTAL 5–12 13–24 Mild Moderate 25–36 37+ Moderately severe Severe

Initiation protocol (1) At least 12 hours since last oral dose Patient reports typical withdrawal symptoms COWS score 12+ First dose: 4 mg SL (takes several minutes to dissolve) Reassess in 2 hours If patient improved but still in withdrawal, give another 4 mg to take in office or at home Maximum dose first day: 12 mg

Initiation protocol (2) Office induction is preferred to ensure patient does not go into precipitated withdrawal If patient cannot attend for office induction, write prescription (2 mg SL q4H PRN, up to 6 tabs over 24 hours, x 1–3 days) and give patient clear instructions: Wait at least 12–16 hours since your last opioid use Make sure your COWS score is at least 12 (give scale) Put 2 tablets under your tongue and let them dissolve Wait 2 hours and measure your COWS score again If still in withdrawal, take another 2 tablets Do not take more than 6 tablets (12 mg) in first 24 hours Next day: Take total first-day amount as single dose

24h Titration Reassess in 1–3 days Increase dose by 2–4 mg at each visit if patients reports withdrawal symptoms/cravings near end of dosing interval Optimal dose should relieve withdrawal symptoms/cravings for 24 hours without significant sedation or other side effects Optimal maintenance dose: 8–16 mg SL OD Maximum maintenance dose: 24 mg SL OD Arrange frequent office visits for counselling and urine drug screen monitoring Screen for presence of norbuprenorphine/absence of other opioid metabolites 24h

Dispensing If possible, buprenorphine should initially be dispensed daily and taken under pharmacist’s observation Especially important if patient has been accessing opioids from other sources Take-doses should be prescribed when patient is at optimal dose and has stopped unauthorized use Consider early take-home doses if patient… Acquires opioids only from physician Does not inject or crush oral opioid tablets Does not buy, sell, or use illicit drugs

Prescriptions Specify pharmacy and send by fax Specify observed and take-home doses

At each office visit Ask about withdrawal symptoms or cravings Sometimes minor dose adjustments required (2–4 mg) Perform urine drug screens Ask about alcohol and cannabis use (usually not tested on urine drug screen) Ask about overall mood and functioning Manage chronic medical conditions (e.g., hepatitis C) or psychiatric conditions (e.g., anxiety, depression) Perform regular screening and health maintenance (e.g., pap tests, mammograms, immunizations, etc.)

Buprenorphine failures Buprenorphine is effective for many patients However, in some cases, it does not fully relieve withdrawal symptoms or suppress opioid use If patient continues to experience withdrawal symptoms/ cravings or use illicit opioids despite an adequate dose of buprenorphine, refer to a methadone clinic that provides high-quality care

Tapering buprenorphine Indications Wants to taper At least six months without any substance use Socially stable, supportive family or social network Stable mood, good coping strategies Protocol Decrease by small amounts (1–2 mg) Leave at least two weeks between dose decreases Hold taper at patient’s request Return to original dose if opioid use restarts Provide regular support and encouragement: it is not a “failure” if taper has to be held/reversed

Wrap-up: Key Messages

Our responsibility Treating addicted patients is our responsibility as health care providers Addiction can occur as a complication of opioid therapy Addiction is the same as any other chronic illness: patients need specialist referrals, medication, treatment of co-occurring conditions, and regular follow-up Effective addiction treatments are available Purpose of META:PHI project is to facilitate adoption of best practices and support clinicians

Resources META:PHI website: www.metaphi.ca META:PHI mailing list for clinical questions and discussion (e-mail sarah.clarke@wchospital.ca to join) META:PHI contacts: Medical lead: Dr. Meldon Kahan meldon.kahan@wchospital.ca Manager: Kate Hardy kate.hardy@wchospital.ca Knowledge broker: Sarah Clarke sarah.clarke@wchospital.ca